A promising medication , retatrutide, is sparking considerable excitement within the Aussie weight management community. Designed by Eli Lilly , this dual GIP and GLP-1 agonist appears to provide more substantial benefits than current therapies. Preliminary medical studies have shown remarkable decreases in overall fat , suggesting the potential fo